Metagenomi Therapeutics, Inc. (MGX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US59102M1045
Metagenomi Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 25.21 m USD |
| Operating income | -96.01 m USD |
| EBIT | -97.40 m USD |
| Net income | -87.87 m USD |
| Diluted EPS – continuing operations | -2.36 USD |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs. The company was formerly known as Metagenomi, Inc. and changed its name to Metagenomi Therapeutics, Inc. in January 2026. Metagenomi Therapeutics, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.
More stocks
- Amicorp FS (UK) PLC (AMIF.L)
- RADNOSTIX INC (INIS)
- AURA SYSTEMS INC (AUSI)
- Edesa Biotech, Inc. (EDSA)
- Adicet Bio, Inc. (ACET)
- AMERICAN VANGUARD CORP (AVD)
- Xos, Inc. (XOS)
- Mono Next Public Company Limited (MONO.BK)
- ATLANTIC AMERICAN CORP (AAME)
- Tonix Pharmaceuticals Holding Corp. (TNXP)
- CervoMed Inc. (CRVO)
- Lite Strategy, Inc. (LITS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.